“The Cambridge hub is a tangible commitment and an important addition to our research footprint – complementing the strong and active research already taking place in Denmark and marking another important step in our ambition to become a leader in obesity and metabolic health,” says Adam Steensberg, President and Chief Executive Officer of Zealand Pharma.

The new hub will enhance the company’s research platform through AI-driven drug discovery, advanced automation, and next-generation molecule creation, accelerating the translation of scientific insight into innovative medicines, the company states. It will expand the research platform beyond the company’s core peptide expertise, adding hybrid modalities for tissue-selective targeting such as antibody-peptide conjugates (APCs) and siRNAs. Zealand Pharma is now actively recruiting to the site in Cambridge.

“We are excited to build our research hub where the metabolic expertise of Denmark and multi-modal platform capabilities from Cambridge can come together,” says Utpal Singh, Chief Scientific Officer of Zealand Pharma. 

In addition to the research laboratories, Zealand Pharma’s Cambridge site will include office space, meeting rooms, and collaborative areas for colleagues from across the organization, as the company expands its presence in the US, it states.